Drug Profile

Gallium-68 pasireotide - Ipsen

Alternative Names: 68Ga-pasireotide tetraxetan; Gallium-68-pasireotide tetraxetan

Latest Information Update: 08 Nov 2018

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Novartis
Developer Ipsen
Class Cyclic peptides; Imaging agents; Macrocyclic compounds; Oligopeptides; Radiopharmaceutical diagnostics
Mechanism of Action Positron-emission tomography enhancers

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Gastro-enteropancreatic neuroendocrine tumour
New Molecular Entity No

08 Nov 2018 Discontinued - Preclinical for Gastro-enteropancreatic neuroendocrine tumour (Diagnosis) in Germany (IV)
16 Jul 2016 No recent reports of development identified for preclinical development in Gastro-enteropancreatic neuroendocrine tumor (Diagnosis) in Germany (Parenteral)
27 Oct 2011 Preclinical trials in Gastro-enteropancreatic neuroendocrine tumour (diagnosis) in Germany (IV)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com